Compositions comprising constituents, derivatives or extracts of cannabis
US-2024415913-A1 · Dec 19, 2024 · US
The use of phytocannabinoids in the treatment of ovarian carcinoma
US2016136128A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016136128-A1 |
| Application number | US-201414899613-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 19, 2014 |
| Priority date | Jun 19, 2013 |
| Publication date | May 19, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are used in combination with each other. Preferably the combination of cannabinoids consists of CBD and CBG.
First claim
Opening claim text (preview).
1 . A method for treatment of ovarian cancer comprising administering one or more phytocannabinoids to a patient with ovarian cancer. 2 . The method in claim 1 , wherein the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV). 3 . The method in claim 1 , wherein the phytocannabinoid is CBG. 4 . The method in claim 1 , wherein the one or more phytocannabinoids are used in combination with each other. 5 . The method in claim 4 , wherein the combination of phytocannabinoids is CBD in combination with CBG. 6 . The method in claim 4 , wherein the combination of phytocannabinoids is CBD in combination with THCV. 7 . The method in claim 1 , wherein the phytocannabinoids are in the form of an extract or botanical drug substance. 8 . The method as claimed in claim 1 , wherein the phytocannabinoids are in an isolated or pure form. 9 . (canceled) 10 . (canceled)
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
3,4-Dihydrobenzopyrans, e.g. chroman, catechin · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Cannabis · CPC title
- A61K31/658Primary
o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016136128A1 cover?
- The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are …
- Who is the assignee on this patent?
- Gw Pharma Ltd, Otsuka Pharma Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/658. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu May 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).